Yili says precision dairy will hinge on nutritional conversion capability

Yili Group is making a blunt argument for where dairy protein is headed: the next advantage will not come from volume alone, but from what Ignatius Szeto calls nutritional conversion capability. In a June 18 interview, Szeto said the sector is shifting toward high-value nutrition and away from a one-size-fits-all model, with dairy ingredients being reworked into more targeted products for specific health needs.

At the center of that pitch is lactoferrin, a bioactive protein Yili says it has spent more than a decade developing for industrial-scale production as a high-purity, high-yield, high-activity powder. Szeto framed lactoferrin as a proof point for how dairy can be re-engineered, not just extracted, by using advanced processing to unlock, restructure and amplify ingredient value. He also pointed to work in natural cheese and demineralised whey, a sign that Yili’s nutrition strategy extends beyond one headline ingredient.

The company’s line is not just about premium branding. Yili reported FY2025 revenue of RMB 115.931 billion and net profit attributable to parent owners of RMB 11.565 billion, up 36.82% year on year, giving it the balance sheet to keep pushing specialized nutrition at scale. At the April 2026 Global Dairy Congress, Szeto delivered a keynote on population-based nutrition-driven dairy innovation and healthy aging, which makes clear this is being positioned as a long-term platform, not a side project.

Szeto said consumers are looking for targeted solutions tied to gut health, immune support, weight management and bone, joint and muscle health. That points toward dairy products designed for precise consumer segments and life stages, rather than broad household use. It also means Yili has to connect R&D, large-scale production and end-use applications if the concept is going to move beyond conference language.

There is substance behind the claim. Peer-reviewed reviews describe lactoferrin as an iron-binding glycoprotein with immune-regulatory, anti-inflammatory, antibacterial, antiviral and antioxidant properties, and a 2025 systematic review and meta-analysis said oral lactoferrin supplementation may reduce some infection-related morbidity in children. Chinese media has also reported that Yili developed independent lactoferrin extraction technology with activity retention above 90 percent. Add in a recent review that treats dairy as a carrier for high-quality protein, lactoferrin, CLA, calcium-vitamin D complexes and probiotics, and Yili’s roadmap looks less like a slogan than a plausible next phase for premium dairy, especially if the company can keep turning technical capability into products consumers can actually use.